Understanding how immune-targeting therapies affect glioblastoma tumors
Official title: Impact of immune-targeting therapies on the GBM tumor immune interface
Funded at Massachusetts Institute of Technology · NIH-11073995 · Data updated 2026-11-12
This study is looking at how brain tumor cells, immune cells, and nerve cells work together to understand why some treatments for glioblastoma don’t work well, with the goal of creating better therapies that could help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $158,504 |
| NIH project number | 3U54CA283114-02S1 |
| Project ID | NIH-11073995 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates the complex interactions between neurons, immune cells, and glioblastoma tumor cells to uncover why current immunotherapy strategies often fail. By analyzing these interactions, the study aims to develop a comprehensive computational model that reflects the tumor microenvironment. This model will be built using various biological systems and validated with human patient data, ultimately aiming to enhance treatment strategies for glioblastoma. Patients may benefit from insights that could lead to more effective therapies targeting their tumors.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with glioblastoma by enhancing the effectiveness of immune-targeting therapies.
How similar studies have gone: Other research has shown promise in understanding tumor-immune interactions, but this approach aims to provide a novel, comprehensive model specifically for glioblastoma.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: White, Forest M — Massachusetts Institute of Technology
- Study coordinator: White, Forest M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.